This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
Clinical Epigenetics Open Access 04 February 2023
-
Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
Experimental Hematology & Oncology Open Access 26 May 2017
-
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
Journal of Hematology & Oncology Open Access 18 April 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nishizawa M, Kataoka K, Goto N, Fujiwara KT, Kawai S . v-maf, a viral oncogene that encodes a ‘leucine zipper’ motif. Proc Natl Acad Sci USA 1989; 86: 7711–7715.
Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T et al. Frequent dysregulation of c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457–4463.
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Over expression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191–199.
Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005; 24: 6936–6944.
Avet-Loiseau H, Facon T, Grobois B, Magrangeas F, Rapp MJ, Harousseau JL et al. Intergroupe Francophone du Myelome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185–2191.
Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.
Chang H, Samiee S, Qi WY, Yi QL, Mikhael J, Chen C et al. Genetic risk identifies myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005; 36: 793–796.
Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S . Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353–355.
Acknowledgements
This study was supported by a grant from Cancer Research Society Inc. and a grant from Leukemia and Lymphoma Research Society of Canada to HC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chang, H., Qi, Q., Xu, W. et al. c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. Leukemia 21, 1572–1574 (2007). https://doi.org/10.1038/sj.leu.2404669
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404669
This article is cited by
-
Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
Clinical Epigenetics (2023)
-
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
Journal of Hematology & Oncology (2017)
-
Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
Experimental Hematology & Oncology (2017)
-
t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
Blood Cancer Journal (2015)
-
MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients
Leukemia (2009)